Helix BioPharma Announces the Appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its Board of Directors



    




    
    AURORA, Ontario, Aug. 17 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP /
OTCQX: HXBPF) today announced the appointment of Kazimierz Roszkowski-Sliz,
M.D., Ph.D., to its board of directors. Professor Roszkowski-Sliz is replacing
Professor Slawomir Majewski, who has stepped down from the board to assume the
advisory role of European medical director for Helix.

    Professor Roszkowski-Sliz is an expert in the field of lung disease and
lung cancers, and is a director at the National Tuberculosis and Lung Diseases
Research Institute in Warsaw where he is also head of the clinical department.
 In addition, Professor Roszkowski-Sliz consults on lung diseases issues for
the Polish Ministry of Health.  He received his M.D. from the Medical Academy
in Warsaw and his Ph.D. from the Postgraduate Medical Center in Warsaw.  He is
an accomplished researcher with over 230 published papers.

    "Professor Roszkowski-Sliz is an excellent addition to our board of
directors," said Donald H. Segal, Ph.D., chairman and CEO of Helix BioPharma. 
"His expertise in lung disease, especially lung cancer, will be invaluable to
Helix as we continue to drive our L-DOS47 non-small cell lung cancer program
towards clinical development.  We also want to thank Professor Majewski for
his service on the board.  We are fortunate that he will continue to provide
us with guidance on our European clinical development activities."

    "Helix's novel approach to the challenging problem of lung cancer is a
very interesting and innovative one," said Professor Roszkowski-Sliz.  "I am
looking forward to working with the rest of the board and the management team
to help guide L-DOS47 into and through the clinical development process."
    

    About Helix BioPharma Corp.

    
    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy.  The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies.  Helix's product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate.  Helix is listed
on the TSX and FSE under the symbol "HBP" and on the OTCQX International
Market under the symbol "HXBPF".
    

    For further information contact:
    

    
    Investor & Media Relations
    Ian Stone
    Russo Partners LLC
    Tel: (619) 814-3510
    Fax: (619) 955-5318
    Email: ian.stone@russopartnersllc.com
    

    
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel: (212) 845-4226
    Email: robert.flamm@russopartnersllc.com
    www.russopartnersllc.com


    Editor's Note: Photograph is available on request

    
    This News Release contains certain forward-looking statements and
information regarding the Company's product development initiatives and in
particular, its L-DOS47 new drug candidate, which statements and information
can be identified by the use of forward-looking terminology such as
"continue", "drive", "towards", "forward", "guide", "into and through the
clinical development process", "developing", or variations thereon, or
comparable terminology referring to future events or results. Forward looking
statements and information are statements and information about the future and
are inherently uncertain. Helix's actual results could differ materially from
those anticipated in these forward-looking statements and information as a
result of numerous risks and uncertainties including without limitation, the
Company's need for additional capital which, if not obtained in a timely
manner or at all, will have a material adverse impact on the Company, its
research and development programs and ultimately, its ability to continue; 
the impact of the global economic downturn and credit crisis which have
negatively affected the availability of additional capital, particularly for
development stage biotechnology companies such as Helix; uncertainty whether
L-DOS47 or Topical Interferon Alpha-2b will be successfully developed and
commercialized as a drug or at all; the need for additional pre-clinical and
clinical research and development, which may not be successful or completed in
a timely manner; manufacturing and upscaling risks, including the possibility
that further challenges may arise in connection with the manufacture of
clinical batches of L-DOS47 or Topical Interferon Alpha-2b which could further
delay or otherwise negatively affect the Company's planned development
programs; the risk of obtaining negative findings or factors that may become
apparent during the course of research or development, which may result in the
discontinuation or delay of the research or development projects; the need for
future clinical trials, the occurrence and success of which cannot be assured;
 product liability and insurance risks; the risk of technical obsolescence;
the need for further regulatory approvals, which may not be obtained in a
timely matter or at all; intellectual property risks; Helix's dependence on
numerous third parties, including without limitation, contract research
organizations, contract manufacturing organizations, clinical trial
consultants, collaborative research consultants, regulatory affairs advisors,
and others, whose performance and interdependence can critically affect the
Company's performance and the achievement of its milestones;  Helix's
dependence on its licensor of the L-DOS47 antibody, and on the antibody
license granted to Helix, for the continued development of L-DOS47; the need
to secure new strategic relationships, which is not assured, to commercialize
L-DOS47 and any other drug candidates which may arise out of DOS47; the risk
that the Company's license optionee for Topical Interferon Alpha-2b may not
continue to provide the Company with interferon alpha-2b or exercise its
option, which would have a negative effect on the further development of the
drug candidate and on the Company; the risk of unanticipated expenses or
unanticipated reductions in revenue, or both; the effect of competition;
uncertainty of the size and existence of a market opportunity for Helix's
products; and the risk of changes in business strategy or development plans.
Such risks and uncertainties, and others affecting the Company which could
cause actual results to vary materially from current results or those
anticipated in forward-looking statements and information, are more fully
described in the Company's latest Annual Information Form, MD&A and other
reports filed with the Canadian Securities Regulatory Authorities from time to
time at www.sedar.com, and in the Company's Form 20-F and other reports filed
with the U.S. S.E.C. from time to time (see www.sec.gov/edgar.shtml). 
Forward-looking statements and information are based on the beliefs,
assumptions, opinions and expectations of Helix's management at the time they
are made, and Helix does not assume any obligation to update any
forward-looking statement or information should those beliefs, assumptions,
opinions or expectations change, except as required by law.
    





    




For further information:

For further information: Investor & Media Relations, Ian Stone, Russo
Partners LLC, +1-619-814-3510, Fax: +1-619-955-5318,
ian.stone@russopartnersllc.com; or Robert Flamm, Ph.D., Russo Partners LLC,
+1-212-845-4226, robert.flamm@russopartnersllc.com Web Site:
http://www.helixbiopharma.com

Organization Profile

HELIX BIOPHARMA CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890